D
iabetes is the most important cause of end-stage renal disease (ESRD) in industrialized countries, reflecting the rapidly growing number of patients with adult-onset diabetes (1, 2) . The incidence of type 1 diabetes, however, varies significantly among countries and is the highest in the world in Finland (3) . At the end of 2007, the incidence and prevalence of ESRD due to type 1 diabetes were 13 and 128 per million inhabitants, respectively (4). The latter accounts for 17.2% of patients receiving chronic dialysis. In a recent Finnish study, the risk of ESRD in patients with type 1 diabetes was 2.2% after 20 years and 7.8% after 30 years from the diagnosis of diabetes (5) . In addition, the risk had decreased over the past decades, which is in line with the declining incidence observed in many other countries (6) .
A European study with data from 10 national registries showed a decrease in the mortality rates of patients with type 1 diabetes receiving renal replacement therapy (RRT) during the time period 1991-2000 (7) . In a Danish registry study that covered the time period 1990 -2005, the overall survival rate of patients with diabetes receiving RRT had improved by 15% per 5 calendar years, but the survival rate of patients with type 1 diabetes was not assessed separately per time period (8) . Moreover, registry data from Australia and New Zealand from 1991 to 2005 showed no significant change in the survival of patients with type 1 diabetes receiving RRT over time, although the survival of patients with type 2 diabetes as well as of that of patients without diabetes had improved (9) . The authors also reported that the prognosis of patients with type 1 diabetes remained poor regardless of good access to kidney transplantation. Taken together, despite continuous advances in the management of diabetes and the prevention of diabetic nephropathy, there are only scarce data on whether the prognosis of patients with type 1 diabetes receiving RRT has improved.
Our aim was, therefore, to investigate whether the survival of patients with type 1 diabetes receiving RRT has improved. We used comprehensive data for all patients with type 1 diabetes who had started chronic RRT in Finland during the time period 1980 -2005, which enabled a considerably longer follow-up period than that in previously published studies.
RESEARCH DESIGN AND METHODS -Our incident cohort study included all patients with type 1 diabetes as the cause of renal failure who had started chronic RRT (hemodialysis, peritoneal dialysis, or kidney transplantation) in Finland from 1 January 1980 to 31 December 2005 (n ϭ 1,604). The patients were followed from the day of the first dialysis treatment until death or the end of the follow-up period on 31 December 2007 or until recovery of kidney function or the patients had moved abroad or were lost to follow-up. As a control group we included all patients with chronic glomerulonephritis who had started RRT during the same time period (n ϭ 1,556). The control group was chosen to represent a primary renal disease and hereby obtain information that could separate the impact of development of RRT and diabetes care. Patients with glomerulone-
phritis caused by systemic diseases were excluded.
We used data from the Finnish Registry for Kidney Diseases, which has an estimated 97% coverage of all Finnish patients receiving chronic RRT since 1965. Kidney disease diagnoses have been stored as ICD-9 and later as ICD-10 codes, which enable separation between type 1 and 2 diabetic nephropathy. The registry is maintained by the Finnish Kidney and Liver Association, which is fully financed by the Finnish government. All patients provided written informed consent and permission to use the data anonymously in registry reports and for research purposes.
Data extracted for this study included information on demographics and patient characteristics: age, sex, cause of ESRD, mode of initial RRT (hemodialysis, peritoneal dialysis, or kidney transplantation), information on subsequent kidney transplantation, and cause of death ( Table 1) .
The diagnosis of ESRD was confirmed by kidney biopsy in 80 of the 1,604 patients with type 1 diabetes (5%) and a minimum of 980 of the 1,556 patients with glomerulonephritis (63%). In the glomerulonephritis group, at least 43% had the diagnosis based on biopsy during 1980 -1994 and during 1995-2005 the biopsy incidence was 73-85%, resulting in overall biopsy percentage of at least 63%. A widely accepted clinical practice is to avoid kidney biopsy in patients with type 1 diabetes if there are other signs of microvascular end-organ damage, such as diabetic retinopathy.
A total of 8,719 patients started RRT and of these 18.4% (n ϭ 1,604) had type 1 diabetes and 17.8% (n ϭ 1,556) had glomerulonephritis as the cause of ESRD. The study period was divided into five intervals: 1980 -1984, 1985-1989, 1990 -1994, 1995-1999, and 2000 -2005 . Table 1 describes the study population within these time periods. We further divided the patients into four agegroups based on the age at the start of RRT: Ͻ35 years (444 patients), from 35 to 44 years (586 patients), from 45 to 54 years (383 patients), and Ն55 years (191 patients). A total of six patients with type 1 diabetes and 19 with glomerulonephritis had a kidney transplant as the primary treatment. The majority of these preemptive transplantations took place during 1980 to 1984.
Statistical methods
Comparisons between groups were performed using the 2 test for categorical variables. We calculated survival probabilities with the Kaplan-Meier method, with death as the event, and patients were censored at 31 December 2007 or at the date of last follow-up. Median survival times were estimated from the KaplanMeier curves, and differences in survival probabilities between groups were assessed using the log-rank test. We used Cox proportional hazards regression to perform multivariable modeling of survival probabilities. Two-sided P Ͻ 0.05 was considered statistically significant. For statistical analyses we used SPSS (version 16.0). All possible first-and second-degree interactions between the explanatory variables were considered in the Cox model building.
RESULTS

Descriptive results
The patients with type 1 diabetes showed a significant increase in median age and an overall decrease in peritoneal dialysis mode. The initial RRT mode was hemodialysis in 46.1%, peritoneal dialysis in 53.5%, and kidney transplantation (preemptive) in 0.4%. Sex distribution remained the same with two-thirds being men. The probability to receive a kidney transplant within 2 years from the RRT start diminished from 60% in 1980 -1984 to 35% in 2000 -2005 (Table 1) . Data are median or %. *P value for the overall significance between the groups of RRT start periods. †At the start of RRT. ‡From the start of RRT.
Crude survival of patients with type 1 diabetes Of the 1,604 patients with type 1 diabetes, 1,047 (65.3%) had died, and 557 patients were censored (alive at the end of follow-up on 31 December 2007, n ϭ 548; regained own kidney function, n ϭ 5; moved abroad, n ϭ 4; and lost to follow-up, n ϭ 0). Cardiovascular causes remained the main cause of death and comprised 65.8% of deaths ( chronic RRT from 3.60 to Ͼ8 years and with similar survival improvement across all age-groups and throughout the follow-up period 1980 -2007 (Fig. 2) . Our results are in line with the observations of Sørensen et al. (8) , who found that the overall survival rate of ESRD patients with type 1 or type 2 diabetes had improved by 15% per 5 calendar years. Our findings are also in accordance with an earlier European study by van Dijk et al. (7) that included a larger number of patients with ESRD but had a markedly shorter follow-up time, in which there was only a modest age-and sex-adjusted 2-year mortality reduction for all patients with type 1 diabetes, but a more pronounced 49% reduction in those patients that received a kidney transplant comparing years 1991-1994 to 1995-1998. Our study, however, is the first focusing only on patients with type 1 diabetes and expanding the observation period to almost three decades.
It is noteworthy that the prognosis in this cohort improved over time despite the fact that some patient characteristics were changing in a direction that should be unfavorable with regard to prognosis. In particular, the median age of patients with type 1 diabetes increased by nearly 10 years over the duration of our study period, and the glomerulonephritis group aged to an even greater extent. The proportion of elderly subjects increased in both groups. Mean age of patients at the time of type 1 diabetes diagnosis, however, has not changed, but the time before development of ESRD has increased (5). We also observed a diminishing proportion of patients starting peritoneal dialysis, which is the treatment mode that correlated with the better prognosis. Moreover, the probability of receiving a kidney transplant declined clearly. Thus, the improved prognosis could possibly be explained by better overall management of the patients with chronic kidney disease before and during RRT, as well as by developments in dialysis techniques and diabetes care.
During the follow-up time of our study, the number of patients with type 1 diabetes starting RRT in Finland has increased from 205 in 1980 -1984 to 440 in 2000 -2005. Their relative proportion, however, out of all patients starting RRT has decreased progressively from 22 to 15%. Despite the decreasing relative incidence, the relative prevalence of patients with type 1 diabetes of all patients receiv- ing RRT has remained constant at ϳ17%. This confirms the improved survival of patients with type 1 diabetes receiving RRT as shown in our current study.
To estimate the possible effect of progress in diabetes care, we chose patients with glomerulonephritis as the control group because it is obvious that among patients with glomerulonephritis an improved prognosis could not be caused by better diabetes care. Furthermore, we excluded patients with systemic glomerulonephritis because they could be regarded as potentially sicker than patients with disease affecting only the kidneys. We found a more substantial survival benefit over time for patients with type 1 diabetes compared with patients with glomerulonephritis, indicating that advances in diabetes care and management of diabetes complications may have partly contributed to our observation of improved prognosis of patients with type 1 diabetes.
Over the last few decades, management of diabetes has evolved remarkably in terms of insulin regimens and more intensive blood glucose monitoring. Disposable insulin syringes became widely available in the early 1970s, and home glucose monitoring and semisynthetic and synthetic human insulin reached wider use in the 1980s. With the emergence of multiple insulin injections in the 1990s followed by the development of rapid-acting insulin regimens, patients with type 1 diabetes were able to maintain more stable blood glucose control and closer-to-target A1C levels. In our study population, however, the level of A1C has shown only slight changes during the past years: the mean value was 8.4% in 1992 (when these data were routinely gathered for the first time) and was almost the same in 2007 (8.0%). Nevertheless, this finding does not exclude other potential improvements such as fewer hypo-and hyperglycemic events, with probable beneficial effects on mortality. By taking into account the obvious developments in diabetes care, it is likely that the level of A1C was higher in the 1980s, thus increasing the likelihood of a negative outcome in these patients.
On the other hand, quality and dose of dialysis therapy have also improved over the years. During the 1980s most hemodialysis patients were treated with basic techniques and low-flux cellulosic dialyzers, with no access to on-line hemodiafiltration or modern synthetic high-flux dialyzers with better biocompatibility. Use of these has been expanding since the mid-1990s, allowing enhanced uremic toxin clearance and flexibility of hemodialysis treatment. With peritoneal dialysis therapy, the present availability of biocompatible fluids with better tolerability and solute removal and icodextrin-containing fluid (with superior ultrafiltration capability without excess glucose load) has increased the efficacy of peritoneal dialysis. In addition, the number of patients receiving peritoneal dialysis using automated overnight peritoneal dialysis machines has increased, leading to 1) greater toxin clearance, 2) better adjustment of peritoneal dialysis to everyday life with improved adherence and overall patient compliance to therapy, and 3) possibly diminished peritonitis episodes (10, 11) . In our patient population with type 1 diabetes, the mean number of weekly hemodialysis sessions increased from 2.9 (95% CI 2.8 -3.0) to 3.1 (95% CI 3.0 -3.3) from 1992 to 2007, with mean weekly treatment hours rising from 11.4 (95% CI 10.9 -12.0) to 13.5 (95% CI 12.8 -14.2). During the same time the percentage of those patients with type 1 diabetes who entered peritoneal dialysis therapy and initially used an automated machine rose from 2 to 27. It is a wellknown fact that achieving target uremic toxin clearance improves survival in patients receiving dialysis (12) , and thus the increase in dialysis dose could have led to improved survival in our study population. The dialysis dose, however, was approximately the same both for the patients with type 1 diabetes and patients with glomerulonephritis, suggesting that any survival advantage related to progress in dialysis technology should be similar in both groups.
It could also be speculated that patients with type 1 diabetic nephropathy are in more intensive monitoring by health care professionals compared with patients without diabetes. Patients with type 1 diabetes are closely followed up from childhood with routine visits to the health care system, which probably have preventive effects on cardiovascular complications (13) . The comprehensive management of patients approaching ESRD includes control of blood pressure and calcium-phosphorus level and treatment with erythropoiesis-stimulating agents, which are known to have an effect on cardiovascular outcomes (14) . However, in acknowledging that ϳ66% of those pa- tients with type 1 diabetes who died during our study period died of cardiovascular causes, there is a need for further studies to explore how comorbidities and other related factors before and during ESRD influence the outcome of patients receiving RRT. Our study has some limitations. First, the results might not be generalizable to other countries, as the incidence of type 1 diabetes is among the highest in the world in Finland. Therefore, much attention has been focused on improving quality of diabetes care, which may explain part of the favorable progress in prognosis of the Finnish patients. Second, for most of the patients with type 1 diabetes we did not have kidney biopsy confirmation of the diagnosis because the long-term practice in Finland is to perform a biopsy only in rare patients when other microvascular, diagnosis-confirming findings are absent. Third, we did not have data on patient level details of diabetes treatment (e.g., type of insulin or type of blood pressure medication) or dialysis treatment (e.g., type of vascular access). Thus, we do not exactly know which aspects of treatment improvement have been responsible for the improved prognosis. On the other hand, the strength of the study is that it is based on an exceptionally comprehensive nationwide database with complete coverage of Finnish patients with ESRD. This excludes selection bias and allows longer follow-up of patients with type 1 diabetes receiving RRT than published before.
In summary, the survival of Finnish patients with type 1 diabetes and ESRD has consistently and significantly improved since the beginning of the 1980s despite the progressively older age of patients starting RRT. During the same time period, survival in the control group (patients with glomerulonephritis) has also improved but to a lesser extent. This result indicates a beneficial contribution of both dialysis-related factors and progress in diabetes care and highlights the importance of comprehensive diabetes care in patients receiving chronic renal replacement therapy.
